Enclomisign
Designed to support ovulation recruitment to manage fertility pathways and alleviate reproductive hormone deficits.
- Categories
- Women's Health · Hormone Therapy
- Active ingredient
- Enclomiphene
- Route
- Oral use
- Form
- Tablet
- Strengths
- 50mg
Prescription and consultation requirements for Enclomisign vary by destination and are determined by the fulfilment partner.
Enclomisign details
- Condition
- Secondary Hypogonadism
- Alternative names
- enclomiphene
- Therapeutic class
- Selective Estrogen Receptor Modulator (SERM)
- Pharmacological class
- Estrogen Antagonist
- Known off-label uses
- male infertility
- Contraindications
- pregnancy; liver disease; ovarian cysts; unexplained abnormal bleeding
- Minor side effects
- hot flashes; headache; nausea
- Moderate side effects
- ovarian enlargement; ovarian hyperstimulation; joint pain
- Serious side effects
- deep vein thrombosis, requires immediate medical attention
- Dosage forms
- Tablet
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Manufacturer
- Signature Pharma
- Onset Time
- 5–10 days
- Duration
- 5 days
- Storage instructions
- Store below 25°C.
- Drug interactions
- Estrogens
- Age restrictions
- Approved for adult females of childbearing age.
Patient summary
designed to support ovulation recruitment to manage fertility pathways and alleviate reproductive hormone deficits.
Mechanism of action
Blocks estrogen feedback loops at the hypothalamus, triggering increased gonadotropin release to stimulate ovarian follicle maturation.
Pregnancy and breastfeeding
TGA Category X: Highly contraindicated during pregnancy. Breastfeeding: May inhibit milk production.